摘要
目的 探讨乳腺癌患者联合检测癌胚抗原125和癌胚抗原153对该病的诊断价值.方法 选取100例乳腺癌患者为乳腺癌组,并选取同期100例乳腺良性病变为乳腺良性组,100例健康体检对象为正常对照组,检测三组癌胚抗原125和癌胚抗原153表达量.结果 乳腺癌组CA153和CA125含量为（78.4±23.76） U/mL、（71.3 ±24.7） U/mL;乳腺良性组癌胚抗原153和癌胚抗原125含量为（13.4±3.7） U/mL、（20.6±12.4） U/mL;正常对照组癌胚抗原153和癌胚抗原125含量为（0.9 ±0.8） U/mL、（19.3±11.3）U/mL;乳腺癌组癌胚抗原153和癌胚抗原125含量明显的高于乳腺良性组和正常对照组,数据的比较差异有统计学意义（F=34.15、28.42,均P＜0.05）;单独检测癌胚抗原153和癌胚抗原125在乳腺癌中的检出率分别为31.0％、24.0％,联合检测癌胚抗原153和癌胚抗原125在乳腺癌中的检出率为66.0％,单独检测癌胚抗原153和癌胚抗原125在乳腺癌中的检出率明显的低于联合检测C癌胚抗原153和癌胚抗原125在乳腺癌中的检出率（F =8.21,P＜0.05）,差异有统计学意义.治疗后乳腺癌患者的癌胚抗原153和癌胚抗原125表达量较治疗前有明显的降低,两组比较差异有统计学意义（t=21.82、22.31,均P＜0.05）.结论 临床中联合检测癌胚抗原125和癌胚抗原153能够有效的提高乳腺癌的诊断效果,联合检测敏感性和特异性更高.同时,联合检测对乳腺癌临床治疗监控也具有一定的意义,值得临床中应用.
Objective To investigate the diagnostic value of CA125 and CA153 for the combined detection of the disease in breast cancer patients.Methods 100 cases of breast cancer patients were selected as the breast cancer group,and the same period 100 cases of benign breast lesions were selected as the benign group,100 cases of normal healthy subjects were selected as the control group.The expression levels of CA125 and CA153 in the three groups were detected.Results CA153 and CA125 levels in the breast cancer group was （78.4 ± 23.76） U/mL,（71.3 ± 24.7） U/mL; The benign group CA153 and CA125 content were （13.4 ± 3.7） U/mL,（20.6 ± 12.4） U/mL;CA153 and CA125 in the normal control group content were （0.9 ± 0.8） U/mL,（19.3 ± 11.3） U/mL; CA153 and CA125 in the breast cancer group were significantly higher than those of the benign group and the normal control group,the difference was statistically significant （F =34.15,28.42,all P ＜ 0.05） ; CA153 and CA125 alone detected in breast cancer detection rate was 31.0 ％,24.0 ％,respectively,combined detection of CA153 and CA125 in breast cancer detection rate was 66.0％,CA153 and CA125 alone detected in breast cancer detection rate was significantly lower than the combined detection CA153 and CA125 in the breast cancer detection rate （F =8.21,P ＜ 0.05）.CA153 and CA125 expression of breast cancer patients after treatment than that of before treatment significantly reduced,and compare the data with statistically significant （t =21.82,22.31,all P ＜ 0.05）.Conclusion The clinical detection of CA125 and CA153 united can effectively improve the diagnosis of breast cancer effect,combined detection of higher sensitivity and specificity.Meanwhile,the combined detection of breast cancer clinical monitoring also ha ssome significance,which is worthy of clinical application.
出处
《中国基层医药》
CAS
2014年第18期2758-2760,共3页
Chinese Journal of Primary Medicine and Pharmacy
